MEI Pharma (MEIP) Competitors $4.42 +0.56 (+14.51%) As of 03:35 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MEIP vs. OTLK, VRCA, ADAP, MIST, SRZN, PYXS, ANRO, JMAC, BMEA, and VNRXShould you be buying MEI Pharma stock or one of its competitors? The main competitors of MEI Pharma include Oncobiologics (OTLK), Verrica Pharmaceuticals (VRCA), Adaptimmune Therapeutics (ADAP), Milestone Pharmaceuticals (MIST), Surrozen (SRZN), Pyxis Oncology (PYXS), Alto Neuroscience (ANRO), Maxpro Capital Acquisition (JMAC), Biomea Fusion (BMEA), and VolitionRx (VNRX). These companies are all part of the "pharmaceutical products" industry. MEI Pharma vs. Its Competitors Oncobiologics Verrica Pharmaceuticals Adaptimmune Therapeutics Milestone Pharmaceuticals Surrozen Pyxis Oncology Alto Neuroscience Maxpro Capital Acquisition Biomea Fusion VolitionRx Oncobiologics (NASDAQ:OTLK) and MEI Pharma (NASDAQ:MEIP) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability. Do institutionals and insiders hold more shares of OTLK or MEIP? 11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 52.4% of MEI Pharma shares are held by institutional investors. 4.8% of Oncobiologics shares are held by company insiders. Comparatively, 3.1% of MEI Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has better earnings & valuation, OTLK or MEIP? MEI Pharma has higher revenue and earnings than Oncobiologics. Oncobiologics is trading at a lower price-to-earnings ratio than MEI Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncobiologicsN/AN/A-$75.37M-$0.91-2.49MEI Pharma$65.30MN/A$17.78M-$4.75-0.93 Does the media favor OTLK or MEIP? In the previous week, Oncobiologics had 2 more articles in the media than MEI Pharma. MarketBeat recorded 3 mentions for Oncobiologics and 1 mentions for MEI Pharma. MEI Pharma's average media sentiment score of 1.87 beat Oncobiologics' score of 1.08 indicating that MEI Pharma is being referred to more favorably in the news media. Company Overall Sentiment Oncobiologics Positive MEI Pharma Very Positive Is OTLK or MEIP more profitable? Oncobiologics' return on equity of 0.00% beat MEI Pharma's return on equity.Company Net Margins Return on Equity Return on Assets OncobiologicsN/A N/A -271.12% MEI Pharma N/A -77.00%-64.79% Do analysts prefer OTLK or MEIP? Oncobiologics currently has a consensus price target of $9.60, indicating a potential upside of 323.84%. Given Oncobiologics' stronger consensus rating and higher probable upside, analysts plainly believe Oncobiologics is more favorable than MEI Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncobiologics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80MEI Pharma 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility and risk, OTLK or MEIP? Oncobiologics has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500. Comparatively, MEI Pharma has a beta of 0.19, meaning that its share price is 81% less volatile than the S&P 500. SummaryOncobiologics beats MEI Pharma on 8 of the 14 factors compared between the two stocks. Get MEI Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MEIP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MEIP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MEIP vs. The Competition Export to ExcelMetricMEI PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$2.44B$5.50B$9.40BDividend YieldN/A1.79%4.25%4.09%P/E Ratio-0.939.1928.1319.86Price / SalesN/A673.20424.9198.68Price / Cash0.51160.6835.5357.53Price / Book0.894.728.235.71Net Income$17.78M$30.99M$3.24B$257.80M7 Day Performance64.31%0.96%0.66%1.12%1 Month Performance96.01%10.05%8.07%11.30%1 Year Performance52.94%-3.54%28.44%16.88% MEI Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MEIPMEI Pharma2.2111 of 5 stars$4.42+14.5%N/A+37.4%$0.00$65.30M-0.93100Positive NewsGap DownHigh Trading VolumeOTLKOncobiologics2.5333 of 5 stars$2.32+12.1%$9.60+313.8%-73.9%$77.88MN/A-2.5520Positive NewsVRCAVerrica Pharmaceuticals4.4632 of 5 stars$0.82+1.0%$8.00+881.6%-90.5%$75.38M$7.57M-0.6840ADAPAdaptimmune Therapeutics1.9626 of 5 stars$0.28+4.6%$1.35+381.0%-78.7%$74.48M$178.03M-1.04490MISTMilestone Pharmaceuticals2.7377 of 5 stars$1.38-11.5%$7.00+407.2%+1.2%$73.78M$1M-1.7730News CoverageAnalyst RevisionHigh Trading VolumeSRZNSurrozen2.7883 of 5 stars$8.61-1.1%$38.50+347.2%-11.6%$73.73M$11.64M-0.3480News CoveragePositive NewsPYXSPyxis Oncology2.4057 of 5 stars$1.19+2.6%$9.00+656.3%-66.6%$73.72MN/A-0.7560ANROAlto Neuroscience1.9003 of 5 stars$2.71+4.0%$8.50+214.2%-82.7%$73.22MN/A-1.16N/AJMACMaxpro Capital AcquisitionN/A$5.45-4.4%N/A+2,791.7%$73.18MN/A0.002,021Gap DownBMEABiomea Fusion3.4159 of 5 stars$1.94-3.0%$21.40+1,003.1%-65.9%$72.89MN/A-0.5550Analyst ForecastVNRXVolitionRx2.1095 of 5 stars$0.68+2.5%$3.50+411.2%+8.3%$71.20M$1.31M-1.9080News CoverageAnalyst Forecast Related Companies and Tools Related Companies Oncobiologics Alternatives Verrica Pharmaceuticals Alternatives Adaptimmune Therapeutics Alternatives Milestone Pharmaceuticals Alternatives Surrozen Alternatives Pyxis Oncology Alternatives Alto Neuroscience Alternatives Maxpro Capital Acquisition Alternatives Biomea Fusion Alternatives VolitionRx Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MEIP) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MEI Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MEI Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MEIP Stock Alerts